The Indian IPO market continues to shine in 2025, and Influx Healthtech Limited is the newest name catching investor attention. As a rising player in the healthcare manufacturing space, the company’s initial public offering has created significant buzz in both primary and grey markets. In this post, we dive deep into the Influx Healthtech IPO GMP, key financial details, important dates, and what it means for retail investors.
What is Influx Healthtech?
Influx Healthtech is a healthcare manufacturing company engaged in producing nutraceuticals, ayurvedic products, cosmetics, and veterinary supplements. With multiple GMP-certified manufacturing units in Maharashtra, the company serves both domestic and international clients. As the demand for wellness and preventive healthcare grows, Influx Healthtech is strategically positioned in a high-growth sector.
Influx Healthtech IPO Details
-
IPO Opening Date: June 18, 2025
-
IPO Closing Date: June 20, 2025
-
Price Band: ₹91 to ₹96 per equity share
-
Lot Size: 1200 shares
-
Minimum Investment: ₹1,15,200
-
Issue Size: ₹58.57 crore
-
Listing Exchange: NSE SME
-
Expected Listing Date: June 25, 2025
This IPO is one of the most talked-about listings among the latest IPO entries in June 2025 and stands out as a potential opportunity among the today IPO options available.
Influx Healthtech IPO GMP Today
The Influx Healthtech IPO GMP (Grey Market Premium) is currently around ₹40 per share. With the upper price band at ₹96, this indicates a potential listing price of ₹136. Investors are looking at an approximate 41% premium based on current GMP trends.
The GMP reflects the positive sentiment around this IPO and suggests strong demand in the unlisted grey market. However, it's essential to understand that grey market data is unofficial and can be volatile. Still, it offers a good indicator of market interest.
Financial Performance Snapshot
Influx Healthtech has shown consistent growth:
-
FY2023 Revenue: ₹100.10 crore
-
FY2024 Revenue: ₹104.99 crore
-
FY2024 Profit After Tax: ₹13.37 crore
-
The company has maintained a stable profit margin and has a scalable business model with strong infrastructure.
With strong year-on-year revenue growth and an expanding customer base, the fundamentals look promising for long-term investors.
Use of IPO Proceeds
The funds raised through the IPO will be used for:
-
Setting up new manufacturing units for nutraceuticals and veterinary products
-
Purchasing modern machinery for its cosmetics and homecare segment
-
Meeting working capital requirements
-
General corporate purposes
These investments are expected to enhance production capacity and improve operational efficiency.
Why This IPO Stands Out Among the Latest and Upcoming IPOs
Among the upcoming IPO list for June and July, Influx Healthtech stands out because of its niche in healthcare and wellness manufacturing. Unlike tech or real estate IPOs, this company serves multiple industries and has stable product demand across the globe.
It is not just a today IPO opportunity but also represents a well-placed player in the booming healthcare contract manufacturing industry (CDMO).
Should You Invest?
Here are a few reasons to consider investing in the Influx Healthtech IPO:
✔️ Positive GMP indicating strong listing gains
✔️ Consistent financial growth and profitability
✔️ Experienced management and certified manufacturing units
✔️ Operates in a high-growth sector with long-term potential
However, investors should also consider risk factors like competition, regulatory changes, and the relatively high minimum investment cost.
Final Thoughts
The Influx Healthtech IPO GMP suggests a strong debut in the SME segment, backed by robust fundamentals and growing investor interest. Whether you’re looking to invest in the latest IPO, a today IPO, or tracking the upcoming IPO pipeline, this one deserves a closer look.
Always conduct your own research and consider your investment goals before subscribing to any IPO. For those with an appetite for mid-cap healthcare exposure, Influx Healthtech could be a strategic addition to the portfolio.
Post a Comment